ARS Pharmaceuticals, Inc. Increase (Decrease) in Accounts Receivable
ARS Pharmaceuticals, Inc. (SPRY) reported Increase (Decrease) in Accounts Receivable of $21.47 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivable · last filed 2026-08-13
- ARS Pharmaceuticals, Inc. increase (decrease) in accounts receivable for the quarter ending 2026-06-30 was $20.63M, a 55.73% increase year-over-year.
- ARS Pharmaceuticals, Inc. increase (decrease) in accounts receivable for the quarter ending 2026-03-31 was $839.00K, a 25.62% decline year-over-year.
- ARS Pharmaceuticals, Inc. increase (decrease) in accounts receivable for the quarter ending 2025-12-31 was -$11.18M, a 251.00% decline year-over-year.
- ARS Pharmaceuticals, Inc. increase (decrease) in accounts receivable for the quarter ending 2025-09-30 was $14.01M, a 1712.03% increase year-over-year.
- ARS Pharmaceuticals, Inc. increase (decrease) in accounts receivable for fiscal 2025 was $17.20M, a 110.46% increase from fiscal 2024.
- ARS Pharmaceuticals, Inc. increase (decrease) in accounts receivable for fiscal 2024 was $8.18M.
- ARS Pharmaceuticals, Inc. increase (decrease) in accounts receivable for fiscal 2023 was $0.00.
| Period end | Increase (Decrease) in Accounts Receivable 3 month | Increase (Decrease) in Accounts Receivable 6 month | Increase (Decrease) in Accounts Receivable 9 month | Increase (Decrease) in Accounts Receivable 12 month |
|---|---|---|---|---|
| 2026-06-30 | $20.63M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $21.47M 10-Q · filed 2026-08-13 | $10.29M derived: sum of 3 quarters · filed 2026-08-13 | $24.30M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $839.00K 10-Q · filed 2026-05-15 | -$10.34M derived: sum of 2 quarters · filed 2026-05-15 | $3.67M derived: sum of 3 quarters · filed 2026-05-15 | $16.92M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | -$11.18M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $2.83M derived: sum of 2 quarters · filed 2026-03-09 | $16.08M derived: sum of 3 quarters · filed 2026-08-13 | $17.20M 10-K · filed 2026-03-09 |
| 2025-09-30 | $14.01M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $27.25M derived: sum of 2 quarters · filed 2026-08-13 | $28.38M 10-Q · filed 2025-11-10 | $35.78M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $13.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $14.38M 10-Q · filed 2026-08-13 | $21.78M derived: sum of 3 quarters · filed 2026-08-13 | $22.55M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $1.13M 10-Q · filed 2026-05-15 | $8.53M derived: sum of 2 quarters · filed 2026-05-15 | $9.30M derived: sum of 3 quarters · filed 2026-05-15 | $9.30M derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $7.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $8.18M derived: sum of 2 quarters · filed 2026-03-09 | $8.18M derived: sum of 3 quarters · filed 2026-03-09 | $8.18M 10-K · filed 2026-03-09 |
| 2024-09-30 | $773.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $773.00K derived: sum of 2 quarters · filed 2025-11-10 | $773.00K 10-Q · filed 2025-11-10 | $773.00K derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $0.00 10-Q · filed 2025-08-13 | $0.00 derived: sum of 3 quarters · filed 2025-08-13 | |
| 2024-03-31 | $0.00 10-Q · filed 2025-05-14 | $0.00 derived: sum of 2 quarters · filed 2025-05-14 | ||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $0.00 10-K · filed 2025-03-20 | ||
| 2023-09-30 | $0.00 10-Q · filed 2024-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |